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The increased prevalence of chronic kidney disease (CKD) is a
consequence of the accumulation of risk factors, one of
which is hypertension. Here we assessed the prevalence of
CKD according to blood pressure among 232,025 patients
in a Japanese nationwide database with a focus on the
prevalence and risk factors of CKD in prehypertension.
Patients were stratified by blood pressure and included
75,474 with optimal blood pressure (less than 120/
80mmHg); 59,194 with prehypertension and a normal blood
pressure (120–129/80–84mmHg) or 46,547 patients with
high-normal blood pressure (130–139/85–89mmHg); and
50,810 with hypertension (over 140/90mmHg without
anti-hypertensive drugs). CKD was defined as an estimated
glomerular filtration rate of stage 3 or lower or having
proteinuria greater than 1þ by a dipstick method.
The prevalence of CKD among patients with optimal blood
pressure, prehypertension having normal or high-normal
blood pressure, and hypertension was 13.9, 15.6, 18.1, and
20.7% in men, and 10.9, 11.6, 12.9, and 15.0% in women, with
a significant difference between genders at each strata of
blood pressure. In men, but not in women, whose blood
pressure was high-normal, the CKD risk was significantly
greater (odds ratio 1.11) than those with optimal blood
pressure. Obesity (body mass index over 25) was significantly
associated with an increased risk of CKD in both men and
women (odds ratio 1.43 and 1.26, respectively), and there
was an additive effect of obesity and pre-hypertension on
CKD risk in men compared with men with optimal blood
pressure. Thus, the prevalence of CKD increased with the
severity of blood pressure. Prehypertension with high-normal
blood pressure, particularly in conjunction with obesity,
was found to be an independent risk factor of CKD in men.
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Chronic kidney disease (CKD) is now recognized as a major
global public health problem.1,2 It is increasingly apparent
that CKD is associated with increased risk of not only
progression to renal failure but also excess cardiovascular
morbidity and mortality in a manner independent of other
known risk factors.1,2
CKD affects 10–15% of the adult population worldwide.3,4
A recent Japanese survey demonstrated that the prevalence of
CKD increased significantly in men, but not in women, from
the 1970s to the 2000s in the general population.5
The reasons are not well understood, but it is likely that
the increased prevalence of CKD is a consequence of the
accumulation of risk factors, such as hypertension or
metabolic abnormalities including diabetes, dyslipidemia,
and obesity, over the last three decades.5 Furthermore, Japan
is known to have a high incidence of end-stage renal disease,
and the number of patients undergoing dialysis has been
increasing.6,7 The incidence and prevalence of end-stage renal
disease are higher in men than in women in Japan.8,9
Individuals with CKD have reduced life expectancy, and the
social burden of CKD with or without end-stage renal disease
is becoming greater. Accordingly, it should be a public health
priority to identify CKD-prone high-risk subjects in the
general population and to treat risk factors in the initial
phase of CKD in order to prevent and delay the progression
to renal failure. Such efforts would also help to prevent
cardiovascular diseases.
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Hypertension is well established as both a cause and
consequence of CKD.10–12 In Asian countries in particular,
high blood pressure (BP) is the strongest risk factor for renal
outcome.10 A previous study in Japan demonstrated that
there was a linear continuous association between BP and
incidence of end-stage renal disease; even in subjects without
hypertension (i.e., even in subjects with prehypertension:
systolic BP/diastolic BP, 120–139/80–89 mm Hg), there
was a greater risk of future development of end-stage renal
disease compared with the risk in subjects with optimal BP
(o120/80 mm Hg).11 Given the evidence that the risk of
end-stage renal disease is increased throughout the BP
range, understanding the burden of CKD in subjects with
prehypertension could help in promoting prevention and
screening efforts for both CKD and prehypertension.13
Recently, the National Health and Nutrition Examination
Survey in the United States demonstrated that the prevalence
of CKD among those with prehypertension was 17.3%,
compared with 13.4% in those with optimal BP.14 However,
there has been no comparable analysis of a nationwide
database in Japan.
Accordingly, in the present study, we examined the
prevalence of CKD within BP classification using a large
nationwide database of subjects recruited from the national
health checkup system in Japan. In addition, we examined
some clinical characteristics other than BP that are prone to
increase risk of CKD.
RESULTS
Patient characteristics
By reviewing the data from the national health checkup
program in Japan, we identified 346,942 subjects for
whom all the clinical data required for the present analysis
were available. A total of 84,854 subjects with a history
of treatment with anti-hypertensive medications, 12,771
subjects with a previous history of cardiovascular diseases,
and 17,049 subjects with both were excluded from the present
analysis. Moreover, 243 subjects with CKD stage 5 (estimated
glomerular filtration rate (eGFR)o15 ml/min per 1.73 m2)
were excluded. Table 1 shows the clinical characteristics of all
subjects included in the present study (n¼ 232,025, left
column) or the clinical characteristics according to gender
difference (right column).
BP classification
Among the study subjects, 75,474 subjects (32.5%) had
optimal BP, 105,741 subjects (45.6%) had prehypertension
(normal BP: 59,194 subjects, 25.5%; high-normal BP: 46,547
subjects, 20.1%), and 50,810 subjects (21.9%) had hyperten-
sion. As the prevalence of such BP classification differed
between men and women, the clinical characteristics
according to BP classification were described by gender
(Table 2). In accordance with the severity of BP classification,
significant increases of age and body mass index, and
significant decrease in the prevalence of current smoking,
were observed. Information about glucose and lipid para-
meters could be obtained in some subjects, although not all:
according to the severity of BP classification, there were
significant differences in the glucose and lipid parameters
(Supplementary Table S1 online).
CKD and BP classification
A total of 32,692 subjects (14.1%) were diagnosed with CKD,
and 8751 subjects (3.8%) had proteinuria (X1þ ). There was
a gender difference in the prevalence of CKD (17.0% in
men versus 12.2% in women; Po0.001); accordingly,
we determined the relationship between prevalence of CKD
and BP classification separately for each gender (Table 2).
Table 1 | Characteristics of the study population overall (left column) or by gender (right column)
Gender difference
Total subjects (n=232,025) Women (n=142,293) Men (n=89,732) P-value
Age, years 61.8±9.4 62.0±9.1 61.4±9.9 o0.001
Men, n (%) 89,732 (38.7) — 89,732 (100) o0.001
Body mass index, kg/m2 22.6±3.2 22.2±3.2 23.4±3.0 o0.001
Obesity, n (%) 58,061 (25.0) 29,358 (20.6) 28,703 (32.0) o0.001
Current smoker, n (%) 36,058 (15.5) 9912 (7.0) 26,146 (29.1) o0.001
Daily drinker, n (%) 50,495 (21.8) 12,471 (8.8) 38,024 (42.4) o0.001
eGFR, ml/min per 1.73m2 76.9±16.0 76.9±15.9 76.8±16.3 0.57
CKD, n (%) 32,692 (14.1) 17,409 (12.2) 15,283 (17.0) o0.001
Stage 1 and 2, n (%) 7041 (3.0) 3232 (2.3) 3809 (4.2) o0.001
Stage 3, n (%) 25,547 (11.0) 14,117 (9.9) 11,430 (12.7)
Stage 4, n (%) 104 (0.04) 60 (0.04) 44 (0.05)
Proteinuria (X1+), n (%) 8751 (3.8) 3948 (2.8) 4803 (5.4) o0.001
BP measurement
Systolic BP, mmHg 126±17 124±17 128±17 o0.001
Diastolic BP, mmHg 75±11 73±10 77±11 o0.001
Abbreviations: BP, blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.
Data are expressed as the means±SD or percentage. P-values were obtained by an unpaired t-test or w2-test between women and men. Statistical significance was defined as
Po0.05. Obesity was defined as body mass index (BMI)X25 kg/m2, and CKD was defined as eGFRo60ml/min per 1.73m2 and/or presence of proteinuria (X1+).
The proteinuria number in each column includes all stage 1/2 patients plus a few in stage 3/4.
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The prevalence of CKD and/or proteinuria (X1þ ) paral-
leled the severity of BP classification in both genders
(Figure 1). The gender difference of CKD became greater
and more prominent with increasing severity of BP
classification.
Using multiple logistic regression analysis, the odds ratio
for the presence of CKD was estimated. Hypertension
was significantly associated with CKD in both genders.
In contrast, only in men, but not in women, prehypertension
with high-normal BP was significantly associated with an
increased risk of CKD even after adjustment for confounders,
such as age, obesity, current smoking, and daily drinking
(Table 3). We also reanalyzed the results of Table 3 after
adjusting for serum glucose, triglyceride, high-density
lipoprotein, and low-density lipoprotein levels: these factors
had no influence on the association between prehypertension
with high-normal BP and CKD in men (data not shown).
Lifestyle factors, obesity, and CKD
Obesity was positively associated with CKD in both genders,
and eGFR was significantly decreased in the subjects with
obesity compared with those without obesity (76.1±16.2
versus 77.1±16.0 ml/min per 1.73 m2; Po0.001). When we
reanalyzed the risk of CKD conferred by obesity in either the
subjects with low eGFR (o60 ml/min per 1.73 m2) or the
subjects with proteinuria (X1þ ), the conclusion remained
unchanged (data not shown). In contrast, daily drinking was
inversely associated with CKD in both genders. Additional
analysis of the subgroup of subjects for whom daily alcohol
intake data were available (n¼ 70,416 men and n¼ 75,416
women) revealed that the inverse association between daily
drinking and CKD was consistent regardless of the amount of
daily intake (X23 g of ethanol or o23 g of ethanol) in men
(odds ratio (95% confidence interval, CI): 0.77 (0.73–0.80)
and 0.89 (0.84–0.95), respectively; both Po0.001); in women,
the inverse association between daily drinking and CKD was
found only in those with a daily intake of o23 g of ethanol
(odds ratio (95% CI): 0.91 (0.84–0.99); P¼ 0.03).
In women, current smoking status was positively asso-
ciated with CKD. In contrast, among men, current smoking
was inversely associated with CKD; that is, male current
smokers had a significantly higher level of eGFR than current
non-smokers (mean (95% CI) of eGFR: 79.0 (78.8–79.2)
versus 75.9 (75.8–76.1) ml/min per 1.73 m2; Po0.001).
In contrast, there was no significant difference in eGFR
between female current smokers and non-smokers (mean
(95% CI) of eGFR: 77.0 (76.7–77.3) versus 76.9
(76.8–77.0) ml/min per 1.73 m2; P¼ 0.45). When we reana-
lyzed the association of current smoking with the presence
Table 2 | Patient characteristics and BP values according to the BP classification by gender
Women (n=142,293) Men (n=89,732)
Optimal
BP
(n=51,715)
Prehypertension
with normal
BP (n=36,182)
Prehypertension
with high-normal
BP (n=27,348)
Hypertension
(n=27,048) P-value
Optimal BP
(n=23,759)
Prehypertension
with normal
BP (n=23,012)
Prehypertension
with high-normal
BP (n=19,199)
Hypertension
(n=23,762) P-value
Age, years 58.8±10.2 62.7±8.4 64.4±7.5 64.8±7.2 o0.001 59.0±10.7 61.0±10.1 62.9±9.3 63.0±8.8 o0.001
Body mass index, kg/m2 21.4±2.9 22.2±3.1 22.7±3.2 23.2±3.5 o0.001 22.5±2.8 23.3±2.9 23.6±3.0 24.0±3.1 o0.001
Obesity, n (%) 6775 (13.1) 7349 (20.3) 6863 (25.1) 8371 (30.9) o0.001 5256 (22.1) 7168 (31.1) 6689 (34.8) 9590 (40.4) o0.001
Current smoker, n (%) 4852 (9.4) 2234 (6.2) 1488 (5.4) 1338 (4.9) o0.001 7953 (33.5) 6562 (28.5) 5071 (26.4) 6560 (27.6) o0.001
Daily drinker, n (%) 4594 (8.9) 3120 (8.6) 2350 (8.6) 2407 (8.9) 0.33 8059 (33.9) 9428 (41.0) 8713 (45.4) 11,824 (49.8) o0.001
eGFR, ml/min per 1.73m2 77.8±15.9 76.9±15.9 76.1±15.7 75.8±15.8 o0.001 78.1±16.5 77.0±16.1 76.1±16.0 76.0±16.4 o0.001
CKD, n (%) 5619 (10.9) 4204 (11.6) 3540 (12.9) 4046 (15.0) o0.001 3303 (13.9) 3582 (15.6) 3475 (18.1) 4923 (20.7) o0.001
Stage 1 and 2, n (%) 864 (1.7) 672 (1.9) 650 (2.4) 1046 (3.9) o0.001 729 (3.1) 799 (3.5) 814 (4.2) 1467 (6.2) o0.001
Stage 3, n (%) 4774 (9.2) 3516 (9.7) 2874 (10.5) 2983 (11.0) o0.001 2565 (10.8) 2775 (12.1) 2652 (13.8) 3438 (14.5) o0.001
Stage 4, n (%) 11 (0.02) 16 (0.04) 16 (0.05) 17 (0.06) o0.001 9 (0.03) 8 (0.03) 9 (0.04) 18 (0.07) o0.001
Proteinuria (X1+), n (%) 1040 (2.0) 812 (2.2) 796 (2.9) 1300 (4.8) o0.001 872 (3.7) 1003 (4.4) 1013 (5.3) 1915 (8.1) o0.001
BP measurement
Systolic BP, mmHg 107±8 123±4 133±4 149±12 o0.001 109±7 123±4 132±4 148±13 o0.001
Diastolic BP, mmHg 65±7 73±7 77±7 85±10 o0.001 67±7 75±6 79±7 88±10 o0.001
Abbreviations: BP, blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.
Data are expressed as the means±SD or percentage. Obesity was defined as body mass index (BMI)X25 kg/m2, and CKD was defined as eGFRo60ml/min per 1.73m2 and/or
presence of proteinuria (X1+). The proteinuria number in each column includes all stage 1/2 patients plus a few in stage 3/4.
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Figure 1 |Prevalence of chronic kidney disease according to
the blood pressure (BP) classification in women (white bar)
and men (black bar). The gender difference in the prevalence of
chronic kidney disease increased in accordance with the severity
of BP classification. Chronic kidney disease was defined as
estimated glomerular filtration rate (eGFR)o60ml/min per
1.73m2 and/or the presence of proteinuria (X1þ ).
Kidney International (2012) 81, 293–299 295
Y Yano et al.: Prehypertension and chronic kidney disease o r ig ina l a r t i c l e
of proteinuria, there was a positive association between
current smoking and proteinuria in both genders (odds ratio
(95% CI): 1.47 (1.38–1.56) in men and odds ratio (95% CI):
1.89 (1.15–3.11) in women; both Po0.001).
Effect of obesity on the association between CKD and
BP classification
Among subjects without hypertension (n¼ 181,215), the risk
of CKD conferred by prehypertension with high-normal
BP increased when these conditions were accompanied by
obesity (X25 kg/m2) in men (Figure 2a), but not in women
(Figure 2b). Accordingly, we examined whether or not there
was an interaction between obesity and prehypertension with
high-normal BP on CKD risk among subjects without
hypertension. Using a multivariable logistic regression
analysis, we showed that there was an additive effect,
but not a synergistic one, of obesity and prehypertension
with high-normal BP on CKD risk in men (data not shown).
Furthermore, we also examined whether there was an interac-
tion between obesity and hypertension (X140/90 mm Hg) on
CKD risk among all subjects (n¼ 232,025). The results
showed that there was no synergistic interaction in either
gender (data not shown).
DISCUSSION
Prehypertension and CKD
In this nationwide study of 232,025 Japanese aged 20 years or
older, we have demonstrated the prevalence of CKD across
the diagnostic spectrum of BP classification. In the present
study, the prevalence of CKD was 17.0% in men and 12.2%
in women. The prevalence was lower than a previous
Japanese report,5 because the present study excluded treated
hypertensive patients. In particular, we focused on the
prevalence of CKD among subjects with prehypertension
(16.7% in men and 12.2% in women). The prevalence of
CKD among subjects with prehypertension with high-
normal BP was greater in men than in women (18.1% versus
12.9%), and prehypertension with high-normal BP was an
Table 3 | Odds ratio (95% confidence interval) for CKD by gender
Women (n=142,293) Men (n=89,732)
Odds ratio
(95% confidence interval) P-value
Odds ratio
(95% confidence interval) P-value
Age, 10 years 1.39 (1.37:1.42) o0.001 1.82 (1.78:1.87) o0.001
Obesity (0=no, 1=yes) 1.26 (1.22:1.31) o0.001 1.43 (1.38:1.49) o0.001
Current smoker (0=no, 1=yes) 1.34 (1.26:1.43) o0.001 0.90 (0.86:0.94) o0.001
Daily drinker (0=no, 1=yes) 0.92 (0.86:0.98) 0.006 0.78 (0.76:0.81) o0.001
BP classificationa
Optimal BP 1 (Reference) 1 (Reference)
Prehypertension with normal BP 0.95 (0.91:1.00) 0.03 1.01 (0.96:1.07) 0.60
Prehypertension with high-normal BP 1.02 (0.97:1.06) 0.54 1.11 (1.05:1.17) o0.001
Hypertension 1.17 (1.12:1.23) o0.001 1.32 (1.25:1.38) o0.001
Abbreviations: BP, blood pressure; CKD, chronic kidney disease.
Obesity was defined as body mass index (BMI)X25 kg/m2. BP classification was defined as follows: optimal BP, systolic blood pressure (SBP)o120mmHg and diastolic blood
pressure (DBP)o80mmHg; prehypertension with normal BP, SBP 120–129mmHg and/or 80–84mmHg; prehypertension with high-normal BP, SBP 130–139mmHg and/or
DBP 85–89mmHg; hypertension, SBPX140mmHg and/or DBPX90mmHg. Statistical significance was defined as Po0.05.
aBP classification: Odds ratio was adjusted for age, obesity, current smoking, and daily drinking.
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Figure 2 | Logistic regression analysis of chronic kidney
disease risk among subjects without hypertension. The odds
ratio (95% confidence interval) of chronic kidney disease risk in
subjects with or without obesity and/or prehypertension with
high-normal blood pressure (BP) is shown in men (a) and women
(b). The analysis was adjusted for age, current smoking, and daily
drinking. Chronic kidney disease was defined as estimated
glomerular filtration rate (eGFR)o60ml/min per 1.73m2 and/or
the presence of proteinuria (X1þ ). *Po0.001 versus group
(1) and wPo0.001 versus group (3).
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independent risk factor for CKD in men, but not in women,
even after adjustment for confounders.
Evidence is accumulating that prehypertension, and parti-
cularly a high-normal BP range, is associated with a variety
of cardiovascular diseases and cardiovascular-associated and
all-cause mortality;15–17 however, information about the
association of prehypertension with CKD is scarce in Japan.18
Much as in other previous reports worldwide,14–16 older age,
higher prevalence of men, and obesity or obesity-related
metabolic abnormalities were more prevalent in subjects with
prehypertension than those with optimal BP (Table 2). These
characteristics could partly explain the cardiovascular risk of
prehypertesion;15–17 however, our data show that the associa-
tion between CKD and prehypertension with high-normal BP
in men is independent of these confounders.
The increased risk of CKD among prehypertensive
subjects with high-normal BP was recognized only in men;
this means that the parallel increase of CKD in accordance
with the level of severity of BP begins at an earlier phase in
men than in women. This gender difference cannot be fully
explained by the gender differences in metabolic factors or BP
itself. It is speculated that it may be related to gender-specific
differences in glomerular structure, hemodynamic condition,
activity of local cytokines and hormones, gene expression,
and/or the effects of sex hormones on kidney cells.9,19
As shown in several previous reports,10–12 hypertension
(X140/90 mm Hg) is a clear risk factor for CKD in both the
genders. In the present study, we excluded 84,854 subjects
who had been treated with anti-hypertensive medication, and
included 50,810 subjects who had never been treated with
anti-hypertensive medication. This exclusion rate suggests
that about a quarter of hypertensive subjects have not been
treated for their condition. This proportion is substantially
improved as compared with a previous report,20 but more
health promotion to increase awareness and treatment of
hypertension is still considered necessary.
Obesity, BP, and CKD
Obesity is an independent risk factor for CKD both in men
and women (Table 3). Intriguingly, our data indicate that the
risk of CKD conferred by prehypertension with high-normal
BP in men increased when these conditions were accom-
panied by obesity (Figure 2a). There was an additive effect of
obesity and prehypertension with high-normal BP on CKD
risk in men.
Obesity-associated glucose and lipid abnormalities could
partly explain the increased risk of CKD in obesity.21,22
However, our data show that the increased risk of CKD
conferred by obesity was independent of these confounders,
although there was some lack of data on glucose and lipid
parameters. There remain several other possible explanations
for the risk of obesity. First, unmeasured obesity-associated
factors, such as insulin resistance, inflammatory and
oxidative stress, and abnormal adipocytokine production,
may be involved in the increased risk of CKD in obesity.22,23
Second, obesity has a fairly consistent effect on renal
hemodynamics, suggestive of glomerular hypertension.24,25
At an early phase, obesity is associated with an elevated GFR
with a less pronounced increase, or even a decrease, in
effective renal plasma flow, resulting in an increased filtration
rate. This alteration, that is, a predominant decrease
in afferent rather than efferent glomerular tone in obese
subjects, may confer enhanced renal susceptibility toward
damage when BP increase is superimposed.24,25 Obesity-
induced hyperfiltration, if continued for a certain period, can
cause a decline in GFR, which may be one of the reasons why
our data showed that obese subjects had a lower eGFR than
nonobese subjects in both genders.
Lifestyle factors and CKD
Lifestyle factors, such as smoking and drinking, are also
important contributors to CKD.26 In the present study, an
inverse association between CKD and current smoking was
found (Table 3), despite the fact that several previous studies
have identified smoking as an important risk factor in the
promotion and progression of renal dysfunction in healthy
subjects or those with complications.27,28 Our study is a
cross-sectional study, and thus there may have been artifacts
due to the observation of sick subjects after they have
changed their lifestyles. However, the effects of smoking on
eGFR are still controversial.27,29,30 In fact, we observed that
male current smokers had a higher eGFR than male non-
smokers, whereas no such association was found in women.
On the other hand, our present results agree with previous
reports;27,29 in that we found a positive association between
smoking and proteinuria in both genders, suggesting the
possibility that smoking causes endothelial dysfunction,
partly through an inflammatory or oxidative pathway.28,29
It was also unexpected that there was an inverse association
between the BP increase and the prevalence of current
smoking (Table 2); this may have been attributable to one of
the following: (1) Some of the smokers in the hypertensive
group may have had knowledge that they were hypertensive,
and may have ceased to smoke on the advice of their
physicians. (2) There may have been a so-called survival
effect, as smokers who develop hypertension were more likely
to have died and thus not to have been included in the
cross-sectional study. (3) Daytime BP under daily activity
would likely be more elevated in smokers compared with
non-smokers, even when there is no difference in the clinical
or office BP between them (i.e., masked hypertension is more
prevalent in smokers).31
Evidence on the association between CKD and alcohol
intake has been scarce. We found that subjects with a daily
drinking habit had a lower likelihood of CKD compared with
those who had no alcohol intake. We could not assess the
kinds or total amount of alcohol; therefore, to discuss this
issue is beyond the scope of the present research. Further
investigation with prospective or lifestyle interventional
studies, such as smoking cessation studies, are warranted
to better elucidate the impact of smoking or drinking on
renal outcomes.
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Several limitations of our study should be mentioned.
First, we cannot infer a cause–effect relationship based on our
cross-sectional data. Second, only a single measurement
of serum creatinine, as well as only a single assessment of
proteinuria, is not fully accurate, and thus there may be an
underestimation of the true association between CKD and BP
level. Third, subjects who participated in the present survey
were generally healthy individuals who were interested
in their health; therefore, the prevalence of prehyperten-
sion/hypertension or CKD may have been underestimated.
Finally, little is known about the cost-effectiveness
of screening male subjects with prehypertension and
high-normal BP range for CKD; therefore, an additional
study is needed to identify the most appropriate populations
to undergo CKD screening.
CONCLUSION
Using a nationwide Japanese database, we show an increased
prevalence of CKD across the diagnostic spectrum of
hypertension. Among men, even in the state of prehyperten-
sion, high-normal BP, particularly when in conjunction with
obesity, was an independent risk factor for CKD. Considering
the fact that the prevalence of CKD and the incidence of
end-stage renal disease are increasing in Japanese men,5,8,9
these data have important clinical implications; as CKD is
often asymptomatic but progressive, more attention must be
paid to men and women with hypertension or obesity and
to men even with high-normal BP for the early detection and
prevention of CKD, or to delay the progression to renal
failure.
MATERIALS AND METHODS
Study population
The methods of the study are detailed in the Supplementary
Information section online. Briefly, based on a recent survey that
showed that obesity and metabolic syndrome are not uncommon in
Japan (http://www-bm.mhlw.go.jp/houdou/2008/04/h0430-2.html),
the Japanese government started a new health-care strategy that
targeted early diagnosis and intervention for metabolic syndrome
from 2008 (Specific Health Checkups and Guidance System
(Tokutei-Kensin)). In this new health-care system, people diagnosed
with metabolic syndrome are obligated to receive repeated lifestyle
guidance over a 6-month period after an annual health examination.
Thirteen of the prefectures participating in this nationwide
project (Yamagata, Miyagi, Fukushima, Niigata, Tokyo, Kanagawa,
Ibaraki, Osaka, Okayama, Kochi, Fukuoka, Miyazaki, and Okinawa)
agreed on our study purpose and were included in the present
analysis. The population surveyed included a total of 346,942
subjects (41% (n¼ 141,938) were men) above 20 years of age, for
whom all the data necessary for our research purposes were
available—namely, information about age, gender, BP, body mass
index, habitual smoking or drinking, use of anti-hypertensive drugs,
previous history of cardiovascular diseases (i.e., cardiac disease and
stroke), and data about the serum creatinine level and dipstick urine
test for proteinuria. This study was granted ethics approval from the
respective institutional review boards. Data were sent to an
independent data center called the NPO Japan Clinical Research
Support Unit, and verified by trained staff.
Baseline measurement
At the baseline examination, all subjects completed a self-
administered questionnaire about lifestyle factors (current smoking
status, daily drinking), and provided medical information
on treatment with anti-hypertensive drugs and a previous history
of cardiac disease or stroke. The study physicians performed a
physical examination of each subject and rechecked their medical
history to improve the precision of the information.
According to the recommendations of the Ministry of Health,
Labor and Welfare (http://www.mhlw.go.jp/bunya/shakaihosho/
iryouseido01/info03a.html), BP was measured by trained observers
using a standard sphygmomanometer or an automated device on
the right arm after resting for 5 min in a seated position with the
legs not crossed. Conversation and alcohol/caffeine consumption
should also be avoided before measurement. Subjects were classified
according to their BP level as follows: optimal BP (systolic BP/
diastolic BPo120/80 mm Hg), prehypertension32 that comprises
normal BP (systolic BP 120–129 mm Hg, diastolic BP 80–84 mm Hg
or both) and high-normal BP (systolic BP 130–139 mm Hg, diastolic
BP 85–89 mm Hg or both), and treated or untreated hypertension
(systolic BP/diastolic BP X140/90 mm Hg or usage of anti-
hypertensive medication).33
Body height and weight were measured in light clothing without
shoes, and the body mass index was calculated (kg/m2). According
to the Japan Society for the Study of Obesity,34 obesity was defined
as a body mass indexX25 kg/m2.
Blood samples were collected after an overnight fast and were
assayed within 24 h. For the purpose of our study, there were
no missing data on the serum creatinine level, but there was a
substantial lack of data on the glucose and lipid parameters
(Supplementary Table S1 online). Freshly voided urine samples were
tested by the dipstick methods in all subjects. Proteinuria was
defined as 1þ or more.
Definition of CKD
Serum creatinine was assayed by an enzymatic method. eGFR was
derived using the following equation:
eGFR (ml/min per 1.73 m2)¼ 194 age (years)0.287 serum
creatinine (mg/dl)1.094 (if women  0.739).35
Details about this equation are also shown in the Supplementary
Information section. CKD was defined as either the presence of
proteinuria or eGFRo60 ml/min per 1.73 m2. The clinical stages
of CKD were classified according to the recommendations of the
National Kidney Foundation Kidney Disease Outcomes Quality
Initiative guidelines36: Stage 1 or 2 (eGFRX60 ml/min per 1.73 m2
and the presence of proteinuria), Stage 3 (eGFR 30–59 ml/min
per 1.73 m2), Stage 4 (eGFR 15–29 ml/min per 1.73 m2), and Stage 5
(eGFR o 15 ml/min per 1.73 m2).
Statistical analysis
All statistical analyses were performed with the SPSS version 18.0J
software (SPSS, Chicago, IL). The differences of patient character-
istics and BP values according to the BP classification were assessed
using analysis of variance, and categorical parameters were
compared with the w2-test. As there is a significant gender difference
in the prevalence of CKD, we examined the association between
CKD and the severity of BP classification separately in men and
women. The odds ratio and 95% CI of each BP classification group
(optimal BP group (reference) versus prehypertension with normal
BP, prehypertension with high-normal BP, and untreated hyperten-
sion group) were calculated for the presence of CKD by multiple
298 Kidney International (2012) 81, 293–299
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logistic regression analysis. Finally, we used a multivariable logistic
regression analysis to examine the effect of obesity on the association
between CKD and BP classification, as well as whether or not
there was an interaction between obesity and prehypertension with
high-normal BP on CKD risk. Statistical significance was defined as
Po0.05.
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